Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Etragut is indicated for:
Pharmacology
Etrasimod is a sphingosine 1-phosphate (S1P) receptor modulator. It binds with high affinity to S1P receptors 1, 4 and 5 (S1P1,4,5). Its activity on S1P3 is minimal (25-fold lower than Cmax at the recommended dose), and it has no activity on S1P2.
Etrasimod partially and reversibly blocks the ability of lymphocytes to leave the lymphoid organs. This lowers the number of lymphocytes in peripheral blood. How etrasimod produces its therapeutic effects in UC is not known, but it may involve less lymphocyte movement into the intestines.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
The recommended dose of Etrasimod for adults is 2 mg taken by mouth once a day. Swallow the tablet whole. You can take it with or without food. If you miss a dose, just take it at your next scheduled time, and don't double the next dose to make up for it.
Side Effects
The most common side effects of etrasimod, each seen in 5% or more of people, are headache, raised liver test results and dizziness.
Cautions & Contraindications
Warnings & Precautions
Infections: Etrasimod may increase the risk of infections. Get a complete blood count (CBC) before starting treatment. Watch for signs of infection during treatment and for 5 weeks after stopping. If a serious infection develops, consider interrupting treatment. Avoid live attenuated vaccines during treatment and for up to 5 weeks after it. Bradyarrhythmia and atrioventricular conduction delays: Etrasimod may cause a temporary drop in heart rate and delays in AV conduction. Do an electrocardiogram (ECG) before starting, to check for any existing cardiac conduction abnormalities. Consider a cardiology consultation if there are conduction abnormalities, or if the patient is also taking other drugs that lower heart rate. Liver injury: Aminotransferases may rise. Check transaminase and bilirubin levels before starting Etrasimod. Stop the medicine if significant liver injury is confirmed. Macular edema: The risk of macular edema may go up. Evaluate the fundus, including the macula, at baseline, near the start of treatment. Repeat this evaluation from time to time during therapy, and also whenever the patient's vision changes. Consider stopping Etrasimod if macular edema develops. Increased blood pressure: Monitor blood pressure during treatment. Fetal risk: Etrasimod may cause fetal harm. Tell females of reproductive potential about the possible risk to a fetus, and advise them to use effective contraception during treatment and for one week after stopping. Cutaneous malignancies: Examine the skin before treatment or shortly after it starts, and then periodically during treatment, especially if the patient has risk factors. Evaluate any suspicious skin lesion promptly. Posterior reversible encephalopathy syndrome (PRES): If symptoms develop, do a physical and neurological exam and consider an MRI. Respiratory effects: Pulmonary function may decline. Assess it (for example, with spirometry) if clinically indicated. Unintended additive immune system effects from prior treatment with immunosuppressive or immune-modulating drugs: Consider the half-life and mode of action of the earlier therapies. Immune system effects after stopping Etrasimod: If the patient is using immunosuppressants at the same time, monitor for infectious complications for up to 5 weeks after the last dose.
Contraindications
Etrasimod must not be used by anyone who has had a myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III or IV heart failure in the last 6 months. It also must not be used by people who have, or have had, Mobitz type II second-degree or third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial block, unless they have a functioning pacemaker.
Pregnancy & Breastfeeding
There is a pregnancy exposure registry that follows the outcomes of pregnancies in women who were exposed to Etrasimod while pregnant. No data are available on whether etrasimod passes into human milk, what effect it might have on a breastfed infant, or whether it changes milk production. In animal studies, female rats were given etrasimod by mouth during pregnancy and while nursing, and etrasimod was found in the plasma of their offspring. This suggests that etrasimod is excreted in milk.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Storage
Store Etrasimod below 30°C, and keep it away from light and moisture. Keep it out of the reach of children.
Common questions about Etragut 2 mg
What is Etragut 2 mg Tablet?
Etragut 2 mg Tablet is a medicine that contains Etrasimod. It is made by Incepta Pharmaceuticals Ltd. It belongs to the Ulcerative Colitis group of medicines.
What is Etragut used for?
Etragut is used for: Inflammatory Bowel Disease.
What are the side effects of Etragut?
The most common side effects of etrasimod, each seen in 5% or more of people, are headache, raised liver test results and dizziness.
Can I take Etragut during pregnancy or while breastfeeding?
There is a pregnancy exposure registry that follows the outcomes of pregnancies in women who were exposed to Etrasimod while pregnant. No data are available on whether etrasimod passes into human milk, what effect it might have on a breastfed infant, or whether it changes milk production. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
How should I store Etragut?
Store Etrasimod below 30°C, and keep it away from light and moisture. Keep it out of the reach of children.
Is there a cheaper medicine with the same ingredient?
Etragut is already among the lowest-priced brands of Etrasimod at this strength.
Do I need a prescription for Etragut?
Etragut is a prescription (Rx) medicine. Take it as your doctor advises.